Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISION
2024-512003-39-00Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label, single-arm trial of tepotinib in non-small cell lung cancer (NSCLC), sponsored by Merck KGaA. Primary endpoint: Objective response rate (independent review). Started Jul 2024; status: completed.
02
Drugs
tepotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-512003-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512003-39-00.